Ally Bridge Group | Activity

Investment

Biobeat secured a $50M Series B financing to advance commercialization of its cuffless ambulatory blood pressure monitor.

Biobeat

Biobeat Ally Bridge Group

ally-bridge.comDEC 30, 2025

DEC 30, 2025

News

ProMIS Neurosciences appointed Ally Bridge Public Equity President and Portfolio Manager Slanix Paul Alex to its board.

ProMIS Neurosciences board appointment

Ally Bridge Group

ally-bridge.comOCT 22, 2025

OCT 22, 2025

Investment

SetPoint Medical raised $140M in private financing to support commercialization of its rheumatoid arthritis therapy.

Setpoint Medical

Setpoint Medical Ally Bridge Group

ally-bridge.comAUG 11, 2025

AUG 11, 2025

Investment

Epicrispr Biotechnologies secured a $68M Series B to initiate a clinical trial for its epigenetic neuromuscular therapy for FSHD.

Epicrispr Biotechnologies

Epicrispr Biotechnologies Ally Bridge Group

ally-bridge.comMAR 26, 2025

MAR 26, 2025

Investment

Cardiac Dimensions raised $53M in Series E financing for its heart failure treatment device.

Cardiac Dimensions

Cardiac Dimensions Ally Bridge Group

ally-bridge.comMAR 20, 2025

MAR 20, 2025

Investment

VitalConnect secured $100M in financing for its wearable biosensor patient-monitoring technology.

VitalConnect

VitalConnect Ally Bridge Group

ally-bridge.comFEB 20, 2025

FEB 20, 2025

Milestone

Aadi Bioscience transformed its portfolio via in-licensing of a novel ADC portfolio and a $100M sale of Fyarro.

Aadi Bioscience

Aadi Bioscience Ally Bridge Group

ally-bridge.comDEC 19, 2024

DEC 19, 2024

Essay

Published commentary on late-stage investors' role in bringing medtech startups through to commercialization.

Late-stage investors seek to bring medtech startups to the home stretch

Ally Bridge Group

ally-bridge.comAUG 1, 2024

AUG 1, 2024

Investment

Imperative Care completed the initial closing of a Series E financing round of up to $150M.

Imperative Care

Imperative Care Ally Bridge Group

ally-bridge.comJUL 25, 2024

JUL 25, 2024

Investment

Kestra Medical Technologies announced a $196M oversubscribed financing round for its wearable cardioverter defibrillator.

Kestra Medical Technologies

Kestra Medical Technologies Ally Bridge Group

ally-bridge.comJUL 24, 2024

JUL 24, 2024

Investment

Insightec announced a $150M financing round to fund continued growth of its focused ultrasound platform.

INSIGHTEC

INSIGHTEC Ally Bridge Group

ally-bridge.comJUN 18, 2024

JUN 18, 2024

Investment

Endeavor BioMedicines raised a $132.5M oversubscribed Series C financing to advance its precision-medicine pipeline.

Endeavor BioMedicines

Endeavor BioMedicines Ally Bridge Group

ally-bridge.comAPR 24, 2024

APR 24, 2024

Team Change

Ally Bridge Group announced key internal promotions and a new appointment.

Key promotions and new appointment

Ally Bridge Group

ally-bridge.comMAR 4, 2024

MAR 4, 2024

Investment

ProfoundBio raised $112M in oversubscribed Series B equity financing to advance its ADC pipeline.

ProfoundBio

ProfoundBio Ally Bridge Group

ally-bridge.comFEB 13, 2024

FEB 13, 2024

Ally Bridge Group Activity

Biobeat secured a $50M Series B financing to advance commercialization of its cuffless ambulatory blood pressure monitor.

ProMIS Neurosciences appointed Ally Bridge Public Equity President and Portfolio Manager Slanix Paul Alex to its board.

SetPoint Medical raised $140M in private financing to support commercialization of its rheumatoid arthritis therapy.

Epicrispr Biotechnologies secured a $68M Series B to initiate a clinical trial for its epigenetic neuromuscular therapy for FSHD.

Cardiac Dimensions raised $53M in Series E financing for its heart failure treatment device.

VitalConnect secured $100M in financing for its wearable biosensor patient-monitoring technology.

Aadi Bioscience transformed its portfolio via in-licensing of a novel ADC portfolio and a $100M sale of Fyarro.

Published commentary on late-stage investors' role in bringing medtech startups through to commercialization.

Imperative Care completed the initial closing of a Series E financing round of up to $150M.

Kestra Medical Technologies announced a $196M oversubscribed financing round for its wearable cardioverter defibrillator.

Insightec announced a $150M financing round to fund continued growth of its focused ultrasound platform.

Endeavor BioMedicines raised a $132.5M oversubscribed Series C financing to advance its precision-medicine pipeline.

Ally Bridge Group announced key internal promotions and a new appointment.

ProfoundBio raised $112M in oversubscribed Series B equity financing to advance its ADC pipeline.